May 4, 2018 / 10:55 AM / 21 days ago

BRIEF-ImmunoGen Reports Q1 Loss Per Share $0.30

May 4 (Reuters) - ImmunoGen Inc:

* IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2018 OPERATING RESULTS

* Q1 REVENUE VIEW $15.1 MILLION — THOMSON REUTERS I/B/E/S

* Q1 EARNINGS PER SHARE VIEW $-0.25 — THOMSON REUTERS I/B/E/S

* ON TRACK FOR TOP-LINE RESULTS IN FORWARD I PHASE 3 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN FIRST HALF OF 2019

* IMGN779 AND IMGN632 ADVANCING THROUGH DOSE-FINDING EVALUATIONS WITH DATA EXPECTED IN Q4 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below